BIIB — BIOGEN INC. catalysts
Next verified catalyst
2026-09-27 — A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-09-27 in 2mo
ESTIMATED |
READOUT
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whethe
Phase 3 · Lupus Erythematosus, Systemic |
BIIB BIOGEN INC. | Litifilimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-09-30 in 2mo
ESTIMATED |
READOUT
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whethe
Phase 3 · Lupus Erythematosus, Systemic |
BIIB BIOGEN INC. | Litifilimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-10-20 in 3mo
ESTIMATED |
READOUT
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Sym
Phase 2/3 · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus |
BIIB BIOGEN INC. | Litifilimab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|
| 2026-12-01 in 4mo
ESTIMATED |
READOUT
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in A
Phase 3 · Antibody-mediated Rejection |
BIIB BIOGEN INC. | Felzartamab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
|